Pre-market: GBT.PA stock down 24.14% to €9.27 on EURONEXT: watch outlook

GBT.PA stock opened the pre-market session sharply lower after yesterday’s sell-off, trading at €9.27 (-24.14%) on EURONEXT with volume 96,834 shares. The drop follows an earnings update and renewed investor focus on leverage and margins in the Healthcare medical-devices space. We review the catalysts, valuation, technicals and short-term price targets to frame what traders should watch as the session begins in Europe.

Price action and immediate drivers for GBT.PA stock

Guerbet SA (GBT.PA) opened at €11.44 and fell to a day low of €9.27, closing the gap to its year low of €9.27. The one-day move equals -24.14%, with intraday volume at 96,834, almost ten times the average volume of 9,443. The sharp fall connects to the company’s recent earnings announcement on 11 March 2026 and renewed concerns about operating margins, inventory levels and debt metrics in the Medical – Devices industry. Immediate risk sentiment pushed technical indicators into oversold territory, amplifying the sell-off.

Valuation snapshot and fundamentals for GBT.PA stock

At €9.27, Guerbet’s market cap stands near €116,812,373.00 with 12,601,119.00 shares outstanding. Reported EPS is €0.61 and the quoted PE is 15.20. Price-to-book sits near 0.35 while EV/EBITDA is 5.37, indicating the market is pricing in stress but also potential recovery. Key balance items: book value per share €29.53, cash per share €3.98, and debt-to-equity 1.06. These metrics show a thin equity buffer against significant leverage, which likely explains part of the heavy selling.

Technical picture and near-term trading risks for GBT.PA stock

Technical indicators are deeply oversold: RSI 11.48 and CCI -305.01, with MACD at -0.65 (signal -0.39). Bollinger middle band sits at €12.88 and lower band at €10.92, so the current price is below the lower band. Relative volume is 10.25, confirming panic or fast position adjustments. Support is the year low €9.27 and resistance zones cluster near the 50-day average €13.75 and 200-day average €17.00. Short-term traders should manage risk: stop levels and scaled exposure are advisable given the high ATR €0.49.

Meyka Grade & technicals: how we score GBT.PA stock

Meyka AI rates GBT.PA with a score out of 100: 68.83 / 100 — Grade B: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals push the stock into oversold zones while fundamentals show low price-to-book and meaningful debt. Note: these grades are not guaranteed and we are not financial advisors.

Analyst context, sector trends and GBT.PA stock risks

The Healthcare sector (Medical – Devices) shows moderate pressure YTD, and companies with higher leverage are underperforming. Sector performance data show a recent 3M drift and YTD weakness that increases sensitivity to earnings misses. Guerbet’s risks: high working capital (days of inventory 155.26), interest coverage near 1.26, and net debt to EBITDA 3.92. Upside drivers include Dotarem and digital solutions growth and stable free cash flow yield 35.01% which supports recovery if leverage is reduced.

Outlook and price targets for GBT.PA stock

Meyka AI’s forecast model projects a 12-month value of €18.13 and a quarterly model price of €9.41. Using the 12-month forecast versus the current price €9.27, the implied upside is 95.55%. Shorter-term model guidance suggests a monthly pivot near €4.97, reflecting possible downside under continued stress. Forecasts are model-based projections and not guarantees. Traders should weigh near-term volatility against the longer-term model upside and company actions to lower leverage.

Final Thoughts

Guerbet (GBT.PA) is one of the top pre-market losers after a -24.14% move to €9.27 on EURONEXT, driven by earnings scrutiny, leverage concerns and inventory pressure. The fundamentals show low price-to-book 0.35 and attractive free cash flow yield 35.01%, but also high net debt to EBITDA 3.92 and weak interest coverage 1.26, which increase short-term downside risk. Technical indicators are deeply oversold (RSI 11.48) and volume spikes confirm active repositioning by holders. For clarity, Meyka AI’s forecast model projects a 12-month target of €18.13, implying +95.55% from today’s price, while the quarterly model sits near €9.41. Those numbers create a wide risk/reward band: recovery is plausible if management reduces debt and margins improve, but traders should treat the next sessions as high-volatility and scale positions accordingly. For follow-up reading see the Guerrbet company page on Meyka and recent coverage on Investing.com for updates and peer comparisons Guerbet on Investing.com Brazil and the competitor compare tool Investing.com compare. Meyka AI is an AI-powered market analysis platform and provides data-driven context; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.